Natural antibodies and cancer

New Biotechnology

Volumn 25, Issue 5, 2009, Pages 294-298

  Vollmers, H Peter ^a   Brändlein, Stephanie ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BACTERIA; CELL CULTURE; CELL MEMBRANES; DISEASES; PEPTIDES; TUMORS; VIRUSES;

ANTICANCER ACTIVITIES; ANTITUMOR IMMUNITY; CELL SURFACE RECEPTORS; EXCEPTIONAL EVENTS; HARMFUL SUBSTANCES; HYBRIDOMA TECHNOLOGY; IMMUNE SURVEILLANCE; IMMUNOLOGICAL MEMORY;

IMMUNE SYSTEM;

ANTIBODY; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN M;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; APOPTOSIS; CANCER IMMUNOLOGY; CARCINOGENESIS; HUMAN; HYBRIDOMA; IMMUNOLOGICAL MEMORY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION;

EID: 67349283550     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2009.03.016     Document Type: Review

References (79)

1. Ehrlich P. The general significance of the side-chain theory, and its importance in biology and therapy. Spec. Pathol. Ther. 8 (1900) 163-185
2. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol. Today 12 (1991) 154-159
3. Coutinho A., et al. Natural autoantibodies. Curr. Opin. Immunol. 7 (1995) 812-818
4. Casali P., and Schettino E.W. Structure and function of natural antibodies. Curr. Top. Microbiol. Immunol. 210 (1996) 167-179
5. Baumgarth N., et al. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J. Exp. Med. 192 (2000) 271-280
6. Baumgarth N., et al. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin. Immunopathol. 26 (2005) 347-362
7. Marchalonis J.J., et al. Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system. FASEB J. 16 (2002) 842-848
8. Du Pasquier L. Innate immunity in early chordates and the appearance of adaptive immunity. C. R. Biol. 327 (2004) 591-601
9. Nurnberger T., et al. Innate immunity in plants and animals: striking similarities and obvious differences. Immunol. Rev. 198 (2004) 249-266
10. Bohn J. Are natural antibodies involved in tumour defence?. Immunol. Lett. 69 (1999) 317-320
11. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol. Immunol. 37 (2000) 1141-1149
12. Ochsenbein A.F., and Zinkernagel R.M. Natural antibodies and complement link innate and acquired immunity. Immunol. Today 21 (2000) 624-630
13. Martin F., and Kearney J.F. B1 cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol. 13 (2001) 195-201
14. Parkin J., and Cohen B. An overview of the immune system. Lancet 357 (2001) 1777-1789
15. Dunn G.P., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002) 991-998
16. Moretta L., et al. Natural killer cells: a mystery no more. Scand. J. Immunol. 55 (2002) 229-232
17. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J. Exp. Med. 195 (2002) F9-14
18. Viau M., and Zouali M. B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114 (2005) 17-26
19. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1 (2001) 135-145
20. Pasare C., and Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560 (2005) 11-18
21. Janeway Jr. C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54 Pt 1 (1989) 1-13
22. Medzhitov R., and Janeway Jr. C. The Toll receptor family and microbial recognition. Trends Microbiol. 8 (2000) 452-456
23. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20 (2002) 197-216
24. Schatz D.G., et al. V(D)J recombination: molecular biology and regulation. Annu. Rev. Immunol. 10 (1992) 359-383
25. Lewis S.M. The mechanism of V(D)J joining: lessons from molecular, immunological, and comparative analyses. Adv. Immunol. 56 (1994) 27-150
26. Constantinescu A., and Schlissel M.S. Changes in locus-specific V(D)J recombinase activity induced by immunoglobulin gene products during B cell development. J. Exp. Med. 185 (1997) 609-620
27. Gellert M. Recent advances in understanding V(D)J recombination. Adv. Immunol. 64 (1997) 39-64
28. Papavasiliou F., et al. Control of immunoglobulin gene rearrangements in developing B cells. Curr. Opin. Immunol. 9 (1997) 233-238
29. Cedar H., and Bergman Y. Developmental regulation of immune system gene rearrangement. Curr. Opin. Immunol. 11 (1999) 64-69
30. Rothenberg E.V. Stepwise specification of lymphocyte developmental lineages. Curr. Opin. Genet. Dev. 10 (2000) 370-379
31. Milner E.C., et al. Human innate B cells: a link between host defense and autoimmunity?. Springer Semin. Immunopathol. 26 (2005) 433-452
32. Brigl M., and Brenner M.B. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22 (2004) 817-890
33. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5 (2004) 987-995
34. Klein J. Private and public antigens of the mouse H-2 system. Nature 229 (1971) 635-637
35. Zinkernagel R.M., and Doherty P.C. The discovery of MHC restriction. Immunol. Today 18 (1997) 14-17
36. Greaves M. Darwinian medicine: a case for cancer. Nat. Rev. Cancer 7 (2007) 213-221
37. Ben-Aissa-Fennira F., et al. IgM antibodies to P1 cytoadhesin of Mycoplasma pneumoniae are part of the natural antibody repertoire expressed early in life. Immunol. Lett. 63 (1998) 59-62
38. Ochsenbein A.F., et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286 (1999) 2156-2159
39. Ulvestad E., et al. Diagnostic and biological significance of anti-p41 IgM antibodies against Borrelia burgdorferi. Scand. J. Immunol. 53 (2001) 416-421
40. Brandlein S., et al. Cysteine-rich fibroblast growth factor receptor 1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res. 63 (2003) 2052-2061
41. Brandlein S., et al. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 63 (2003) 7995-8005
42. Brandlein S., et al. PAM-1, a natural human IgM antibody as new tool for detection of breast and prostate precursors. Hum. Antibodies 13 (2004) 97-104
43. Vollmers H.P., and Brandlein S. The 'early birds': natural IgM antibodies and immune surveillance. Histol. Histopathol. 20 (2005) 927-937
44. Vollmers H.P., and Brandlein S. Death by stress: natural IgM-induced apoptosis. Methods Find Exp. Clin. Pharmacol. 27 (2005) 185-191
45. Vollmers H.P., and Brandlein S. Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Hum. Antibodies 11 (2002) 131-142
46. Brandlein S., and Vollmers H.P. Natural IgM antibodies, the ignored weapons in tumour immunity. Histol. Histopathol. 19 (2004) 897-905
47. Hensel F., et al. Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res. 59 (1999) 5299-5306
48. Hensel F., et al. A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab. Invest. 81 (2001) 1097-1108
49. Rauschert N., et al. A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab. Invest. 88 (2008) 375-386
50. Vollmers H.P., et al. Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76 (1995) 550-558
51. Hensel F., et al. Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab. Invest. 81 (2001) 1553-1563
52. Brandlein S., et al. CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol. Rep. 11 (2004) 777-784
53. Pohle T., et al. Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res. 64 (2004) 3900-3906
54. Brändlein S., et al. The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized LDL. Mol. Cancer Ther. 6 (2007)
55. Fuster M.M., and Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5 (2005) 526-542
56. Hendershot L.M. The ER function BiP is a master regulator of ER function. Mt. Sinai J. Med. 71 (2004) 289-297
57. Macario A.J., and Conway de Macario E. Sick chaperones, cellular stress, and disease. N. Engl. J. Med. 353 (2005) 1489-1501
58. Delpino A., et al. Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin. Mol. Membr. Biol. 15 (1998) 21-26
59. Ma Y., and Hendershot L.M. The role of the unfolded protein response in tumour development: friend or foe?. Nat. Rev. Cancer 4 (2004) 966-977
60. Misra U.K., et al. The role of MTJ-1 in cell surface translocation of GRP78, a receptor for alpha 2-macroglobulin-dependent signaling. J. Immunol. 174 (2005) 2092-2097
61. Zhai L., et al. Decreased cell survival and DNA repair capacity after UVC irradiation in association with down-regulation of GRP78/BiP in human RSa cells. Exp. Cell Res. 305 (2005) 244-252
62. Li J., and Lee A.S. Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med. 6 (2006) 45-54
63. Gazit G., et al. De-regulation of GRP stress protein expression in human breast cancer cell lines. Breast Cancer Res. Treat. 54 (1999) 135-146
64. Fernandez P.M., et al. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res. Treat. 59 (2000) 15-26
65. Koomagi R., et al. Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas. Anticancer Res. 19 (1999) 4333-4336
66. Uramoto H., et al. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49 (2005) 55-62
67. Song M.S., et al. Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-epsilon/ERK/AP-1 signaling cascade. Cancer Res. 61 (2001) 8322-8330
68. Shuda M., et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J. Hepatol. 38 (2003) 605-614
69. Lim S.O., et al. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J. Gastroenterol. 11 (2005) 2072-2079
70. Miyake H., et al. Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells. J. Cell Biochem. 77 (2000) 396-408
71. Arap M.A., et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6 (2004) 275-284
72. Davis L.S., et al. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J. Immunol. 141 (1988) 2246-2252
73. Kuraya M., and Fujita T. Signal transduction via a protein associated with a glycosylphosphatidylinositol-anchored protein, decay-accelerating factor (DAF/CD55). Int. Immunol. 10 (1998) 473-480
74. Vollmers H.P., et al. SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res. 49 (1989) 2471-2476
75. Mikesch J.H., et al. The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 28 (2006) 223-232
76. Vollmers H.P., et al. Tumor-specific apoptosis induced by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer. Oncol. Rep. 5 (1998) 35-40
77. Vollmers H.P., et al. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol. Rep. 5 (1998) 549-552
78. Illert B., et al. Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer. Oncol. Rep. 13 (2005) 765-770
79. Vollmers H.P., et al. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 79 (1997) 433-440